Breyanzi genetically modified autologous T cells Images
Generic Name: lisocabtagene maraleucel
This medication has been identified as Breyanzi genetically modified autologous T cells. It is supplied by Bristol-Myers Squibb Company.
Breyanzi is used in the treatment of Diffuse Large B-Cell Lymphoma; B-Cell Lymphoma; Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma and belongs to the drug class miscellaneous antineoplastics. Breyanzi genetically modified autologous T cells is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Breyanzi
- Generic Name
- lisocabtagene maraleucel
- Strength
- genetically modified autologous T cells
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Bristol-Myers Squibb Company
- National Drug Code (NDC)
- 73153-0900
More about Breyanzi (lisocabtagene maraleucel)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.